Operator

Good morning, ladies and gentlemen, and welcome to the Smith & Nephew 2012 Q2 and Half Year Results. For your information, this conference is being recorded. At this time, I will turn the call over to your host today, Mr. Olivier Bohuon. Please go ahead, sir.

Olivier Bohuon

Good morning, everyone. This is Olivier Bohuon. I'm here with Adrian Hennah, and welcome to our second quarter results call. I will cover the highlights and then hand over to Adrian to take you through numbers. And when he has finished, I will update you on how we have progressed on delivering our strategic priorities. As usual, we'll take questions at the end.

This quarter, Smith & Nephew again delivered underlying top line growth and an improved trading profit margin in challenging markets, completing a good first half. We are delivering on our financial commitment and implementing our strategic priorities to Smith & Nephew to provide the right commercial model, innovation and efficiencies to win in our market today and the future. Taking into account this combination, we're pleased to announced a substantial step change in our dividend. Our Q2 revenues were up an underlying 2% to $1.029 billion. This is against challenging markets, particularly in Europe. This revenue growth is after the formation if Bioventus, which we completed in the early part of Q2, and Adrian we'll take you through the financial implications. For us, the transaction realizes value for reinvestment in near-term opportunities while retaining access to the exciting area of orthobiologics.

Trading profits increased 6% underlying, to $234 million, giving a 80 basis points improvement in our trading profit margin to 22.7%. This is evidence that the structural improvements we have made to our organization, particularly creating the Advanced Surgical Devices, are beginning to come through. Adjusted earnings per share were $0.181. Our cash generation remains excellent, and the group now has a net cash of $150 million.

If you liked this article you might like

European Stocks Rise but London Blue Chips Slip on Stronger Pound

Take Advantage of U.K. Budget to Bag Some Bargains

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

Perrenial Target and Acquirer NuVasive Names New President and COO

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine